{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:14:41Z","timestamp":1791378881119,"version":"4.3.2"},"reference-count":18,"publisher":"MedWorks Media","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Purpose of Study\nThis retrospective review aimed to evaluate the prevalence of tetrahydrocannabinol (THC)-positive urine drug screens (UDS) in patients undergoing chronic opioid therapy (COT) for chronic pain at a single academic institution. With a growing national trend toward cannabis legalization and increased public access to marijuana for medical and recreational purposes, understanding the intersection between THC use and opioid prescribing practices is essential. The presence of THC on UDS has clinical, legal, and ethical implications, especially in regions where cannabis remains illegal. This study sought to quantify the prevalence of THC positivity in patients receiving COT for chronic pain.\nFindings\nA total of 244 UDS results were reviewed from January 1, 2024, to December 31, 2024. Among these, 24 patients (9.8%) tested positive for THC. Documentation and clinical responses to positive results varied, with some providers documenting patient counseling, while others did not acknowledge the result in the medical record. In a small subset of cases, positive THC findings contributed to changes in opioid therapy, including tapering or discontinuation.\nConclusion\nTHC-positive UDS results are relatively common among patients receiving chronic opioid therapy, highlighting the increasing prevalence of cannabis use in this population. These findings align with prior literature and reinforce the need for individualized, non-punitive approaches to care. Routine screening, consistent documentation, and open communication about cannabis use are essential components of effective opioid risk stratification, safe prescribing practices, and informed treatment planning. These considerations are critical in regions where recreational marijuana remains illegal, which may further influence provider decision-making regarding ongoing opioid therapy.<\/jats:p>","DOI":"10.64719\/pb.4549","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"36-42","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of THC-Positive Urine Drug Screens in Patients Receiving Chronic Opioid Therapy: A Retrospective Review"],"prefix":"10.64719","volume":"55","author":[{"given":"Jamal","family":"Hasoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Viswanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Urits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Abd-Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Manchikanti L, Kaye AM, Knezevic NN et al. Comprehensive, evidence-based, consensus guidelines for prescription of opioids for chronic non-cancer pain from the american society of interventional pain physicians (ASIPP) Pain Physician. 2023;26(7S):S7\u2013S126.","DOI":"10.36076\/ppj.2023.26.S7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014united states, 2016. MMWR Recomm Rep. 2016;2016;6565(1)(11):1\u201349. 295. doi: 10.15585\/mmwr.rr6501e1. Erratum in: MMWR Recomm Rep.","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Bandara S, Bicket MC, McGinty EE. Trends in opioid and non-opioid treatment for chronic non-cancer pain and cancer pain among privately insured adults in the United States, 2012\u20132019. PLoS One. 2022;17(8):e0272142. doi: 10.1371\/journal.pone.0272142.","DOI":"10.1371\/journal.pone.0272142"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Christo PJ, Manchikanti L, Ruan X et al. Urine drug testing in chronic pain. Pain Physician. 2011;14(2):123\u2013143.","DOI":"10.36076\/ppj.2011\/14\/123"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Owen GT, Burton AW, Schade CM, Passik S. Urine drug testing: current recommendations and best practices. Pain Physician. 2012;15(3 Suppl):ES119\u201333.","DOI":"10.36076\/ppj.2012\/15\/ES119"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hameed M, Prasad S, Jain E et al. Medical cannabis for chronic nonmalignant pain management. Curr Pain Headache Rep. 2023;27(4):57\u201363. doi: 10.1007\/s11916-023-01101-w. Epub 2023 Mar 10.","DOI":"10.1007\/s11916-023-01101-w"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther. 2019;8(1):41\u201351. doi: 10.1007\/s40122-019-0114-4. Epub 2019 Feb 5.","DOI":"10.1007\/s40122-019-0114-4"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Wang L, Hong PJ, May C, Rehman Y, Oparin Y, Hong CJ et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021;374:n1034. doi: 10.1136\/bmj.n1034.","DOI":"10.1136\/bmj.n1034"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"McAfee J, Boehnke KF, Moser SM, Brummett CM, Waljee JF, Bonar EE. Perioperative cannabis use: a longitudinal study of associated clinical characteristics and surgical outcomes. Reg Anesth Pain Med. 2021;46(2):137\u2013144. doi: 10.1136\/rapm-2020-101812. Epub 2020 Nov 18.","DOI":"10.1136\/rapm-2020-101812"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999;15(3):184\u2013191. doi: 10.1097\/00002508-199909000-00005.","DOI":"10.1097\/00002508-199909000-00005"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Ives TJ, Chelminski PR, Hammett-Stabler CA et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res. 2006;6:46. doi: 10.1186\/1472-6963-6-46.","DOI":"10.1186\/1472-6963-6-46"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Hariharan J, Lamb GC, Neuner JM. Long-term opioid contract use for chronic pain management in primary care practice. A five year experience. J Gen Intern Med. 2007;22:485\u2013490.","DOI":"10.1007\/s11606-006-0084-1"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"McAfee J, Boehnke KF, Moser SM, Brummett CM, Waljee JF, Bonar EE. Perioperative cannabis use: a longitudinal study of associated clinical characteristics and surgical outcomes. Reg Anesth Pain Med. 2021;46(2):137\u2013144. doi: 10.1136\/rapm-2020-101812. Epub 2020 Nov 18.","DOI":"10.1136\/rapm-2020-101812"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Urits I, Charipova K, Gress K et al. Adverse effects of recreational and medical cannabis. Psychopharmacol Bull. 2021;51(1):94\u2013109.","DOI":"10.64719\/pb.4395"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Petzke F, T\u00f6lle T, Fitzcharles MA, H\u00e4user W. Cannabis-based medicines and medical cannabis for chronic neuropathic pain. CNS Drugs. 2022;36(1):31\u201344. doi: 10.1007\/s40263-021-00879-w. Epub 2021 Nov 21.","DOI":"10.1007\/s40263-021-00879-w"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Urits I, Gress K, Charipova K et al. Cannabis use and its association with psychological disorders. Psychopharmacol Bull. 2020;50(2):56\u201367.","DOI":"10.64719\/pb.4606"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci. 2025;275(2):281\u2013292. doi: 10.1007\/s00406-024-01880-2. Epub 2024 Sep 19.","DOI":"10.1007\/s00406-024-01880-2"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Hadland SE, Levy S. Child Adolesc Psychiatr Clin N Am. 2016;25(3):549\u2013565. doi: 10.1016\/j.chc.2016.02.005. Objective testing: urine and other drug tests. Epub 2016 Mar 30.","DOI":"10.1016\/j.chc.2016.02.005"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:47Z","timestamp":1791315227000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/prevalence-of-thc-positive-urine-drug-screens-in-patients-receiving-chronic-opioid-therapy-a-retrospective-review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4549","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}